Analysts think REGN stock price could increase by 47%
Mar 05, 2025, 12:25 PM
-9.53%
What does REGN do
Regeneron Pharmaceuticals, headquartered in Tarrytown, New York, focuses on developing medicines for serious diseases, employing 13,450 people. Its key products include EYLEA, Dupixent, and Libtayo, utilizing advanced technologies like VelociSuite.
28 analysts think REGN stock price will increase by 46.53%. The current median analyst target is $989.40 compared to a current stock price of $675.22. The lowest analysts target is $580.75 and the highest analyst target is $1209.60.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
